Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillomavirus Infections 1Ovarian Neoplasms 1Neuroblastoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Ganglioneuroblastoma 1Fibrosis 1Breast Screening 1Breast Neoplasms 1

Interventions

Cyclophosphamide 10Magnetic Resonance Spectroscopy 8Temozolomide 6Biopsy 6dinutuximab 5X-Rays 5Topotecan 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Irinotecan 5Etoposide 3Colony-Stimulating Factors 3ulixertinib 2tipifarnib 2selpercatinib 2sargramostim 2pembrolizumab 2palbociclib 2naxitamab 2larotrectinib 2ivosidenib 2fludarabine phosphate 2fludarabine 2etoposide phosphate 2erdafitinib 2ensartinib 2Lenalidomide 2Isotretinoin 2Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neuroblastoma × High-Energy Shock Waves × Clear all
NCT02176967 2026-05-05

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Children's Oncology Group

Phase 3 Active not recruiting
621 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡